Target intelligence / Profile preview

Integrin alpha-3 (ITGA3)

Target
ITGA3
Molecular classification
Receptor, Other
01

Overview

Integrin alpha-3 (ITGA3), also known as CD49c, is a cell surface adhesion receptor that exclusively pairs with the integrin beta-1 (ITGB1) subunit to form the functional alpha-3/beta-1 heterodimer. This integrin complex acts as a primary receptor for extracellular matrix (ECM) proteins, particularly laminins (such as laminin-332), fibronectin, and collagen. It plays a critical role in cell-matrix adhesion, cell migration, tissue organization, and signal transduction. In oncology, ITGA3 is highly overexpressed in various solid tumors, including bladder, breast, pancreatic, ovarian, and head and neck cancers, where it promotes tumor progression, invasion, metastasis, and resistance to chemotherapy and immunotherapy. Consequently, ITGA3 has emerged as an attractive therapeutic target and prognostic biomarker. Therapeutic strategies under development include antibody-drug conjugates (ADCs) like 2E7-MMAE, which exploit the rapid internalization of ITGA3 to deliver cytotoxic payloads, and targeted oncolytic platforms like VAX-014, which utilize engineered bacterial minicells to selectively lyse ITGA3-expressing tumor cells. However, drug development targeting ITGA3 faces significant safety challenges; homozygous loss-of-function mutations in ITGA3 cause ILNEB syndrome, a severe multi-organ disorder characterized by interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, highlighting the potential for severe on-target toxicities in the lungs, kidneys, and skin.

Other names
CD49cCD49 antigen-like family member CFRP-2Galactoprotein B3GAPB3VLA-3 subunit alphaMSK18VCA-2VL3AVLA3a
02

Mechanism of action

Targeted cell lysis via pore-forming protein delivery, antibody-drug conjugation for intracellular payload delivery, and inhibition of cell adhesion and migration

03

Biological functions

Cell adhesionCell migrationSignal transductionCell proliferationCell survival
04

Disease associations

CancerInfectionOther
05

Safety considerations

Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa (ILNEB syndrome)Skin fragility and blisteringRenal dysfunction and proteinuriaPulmonary toxicity and respiratory distress
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Integrin alpha-3 expressionIntegrin alpha-3/beta-1 heterodimer expressionLaminin-332 expression

Beyond the preview

Go deeper on Integrin alpha-3 (ITGA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin alpha-3 (ITGA3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call